Circulating neuregulin-1 and galectin-3 can be prognostic markers in breast cancer [PDF]
, 2017 Background: It is important to identify novel plasmatic biomarkers that can contribute to assessing the prognosis and outcome of breast cancer patients.
Cardelli, Patrizia +5 more
core +1 more source
Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models [PDF]
, 2017 Purpose: Glioblastoma multiforme (GBM) is the most aggressive brain tumor. The activity of vosaroxin, a first-in-class anticancer quinolone derivative that intercalates DNA and inhibits topoisomerase II, was investigated in GBM preclinical models as a ...
Colapietro, Alessandro +11 more
core +1 more source
Role of gemcitabine in the treatment of advanced and metastatic breast cancer [PDF]
, 2003 Gemcitabine is an antimetabolite drug with proven antitumor activity and tolerability in metastatic breast cancer. In a total of nine studies, gemcitabine monotherapy has reached response rates of up to 37% in the first-line setting, 26% in the second ...
Heinemann, Volker
core +1 more source
Uptake of systematic reviews and meta-analyses based on individual participant data in clinical practice guidelines: descriptive study. [PDF]
, 2015 To establish the extent to which systematic reviews and meta-analyses of individual participant data (IPD) are being used to inform the recommendations included in published clinical ...
Cochrane IPD Meta-analysis Methods Group, . +6 more
core +2 more sources
Characteristics of patients with haematological and breast cancer (1996–2009) who died of heart failure-related causes after cancer therapy [PDF]
, 2016 Aims: To describe the characteristics and time to death of patients with breast or haematological cancer who died of heart failure (HF) after cancer therapy.
Atherton, John +8 more
core +2 more sources
BJS (British Journal of Surgery), EarlyView., 2020 This long‐term follow‐up study determined survival rates in a Swedish national cohort of 417 patients with breast cancer who all had neoadjuvant systemic therapy (NAST). Sentinel lymph node biopsy (SLNB) was performed before NAST in clinically node‐negative and after NAST in clinically node‐positive patients.
L. Zetterlund +4 more
wiley +1 more source
Node-positive breast cancer: Which are the best chemotherapy regimens? [PDF]
, 2008 Breast cancer-associated mortality has been significantly reduced since the 1990s, mainly because of early diagnosis and systemic therapeutic interventions.
Bauerfeind, Ingo +5 more
core +2 more sources
Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer. [PDF]
, 2013 Data characterizing demographics, treatment patterns, and clinical outcomes in black patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) are limited.
Abidoye, Oyewale O +8 more
core +1 more source
First-line therapy in HER2 positive metastatic breast cancer. Is the mosaic fully completed or are we missing additional pieces? [PDF]
, 2016 The discovery of human epidermal growth factor receptor 2 (HER2) and its role in the biology of breast cancer and the subsequent development of HER2-targeted therapies, have dramatically improved clinical outcomes for women with early-stage and advanced ...
Cognetti F. +3 more
core +2 more sources
Pregnancy-associated breast cancer - Special features in diagnosis and treatment [PDF]
, 2006 For obvious psychological reasons it is difficult to associate pregnancy - a life-giving period of our existence with life-threatening malignancies. Symptoms pointing to malignancy are often ignored by both patients and physicians, and this, together ...
Bauerfeind, I. +7 more
core +1 more source